SCHEMBL19086436

SCHEMBL19086436

Cc1cc(Br)ccc1C(=O)N1CCN(C(=O)O)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.47
GPR6 P46095 1/20 0.47
ALDH1A1 P00352 4/20 0.45
TP53 P04637 1/20 0.45
HPGD P15428 6/20 0.44
TSHR P16473 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GAA P10253 1/20 0.42
HRH4 Q9H3N8 2/20 0.41
HRH3 Q9Y5N1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1447243 0.88 POLB (0.57) HTTGPR6ALDH1A1TP53HPGD
SCHEMBL4243617 0.87 HTT (0.58) HTTALDH1A1HPGDTSHRPOLB
SCHEMBL256310 0.87 HPGD (0.59) HTTALDH1A1HPGDTSHRPOLB
SCHEMBL2104229 0.86 HPGD (0.59) HTTALDH1A1HPGDTSHRMAPT
SCHEMBL3732153 0.84 DUSP3 (0.54) HTTALDH1A1TP53HPGDSMN1; SMN2
SCHEMBL970089 0.83 HPGD (0.55) HTTHPGDPOLBMAPTKMT2A
SCHEMBL19869975 0.83 RXFP1 (0.48) HTTGPR6HPGDTSHRHRH4
SCHEMBL16098874 0.83 HPGD (0.54) HTTGPR6ALDH1A1TP53HPGD
SCHEMBL1447805 0.82 POLB (0.68) HTTALDH1A1TP53HPGDTSHR
SCHEMBL16129353 0.82 HPGD (0.42) HTTGPR6ALDH1A1TP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3190111-B1 PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-05-06 EP disclosed
US-9975893-B2 Pyrazolo[3,4-c]pyridine derivatives CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2018-05-22 US disclosed
US-20170291896-A1 PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-10-12 US disclosed
EP-3190111-A1 PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2017-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170291896-A1 PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES F11, TFPI, F2 HTT 3756/4885GPR6 3711/4885ALDH1A1 2886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.